Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Avoiding Arterial Hypotension in Preterm Neonates (AHIP)-A Single Center Randomised Controlled Study Investigating Simultaneous Near Infrared Spectroscopy Measurements of Cerebral and Peripheral Regional Tissue Oxygenation and Dedicated Interventions.

Pichler G, Höller N, Baik-Schneditz N, Schwaberger B, Mileder L, Stadler J, Avian A, Pansy J, Urlesberger B.

Front Pediatr. 2018 Feb 1;6:15. doi: 10.3389/fped.2018.00015. eCollection 2018.

2.

Peripheral Muscle Near-Infrared Spectroscopy in Neonates: Ready for Clinical Use? A Systematic Qualitative Review of the Literature.

Höller N, Urlesberger B, Mileder L, Baik N, Schwaberger B, Pichler G.

Neonatology. 2015;108(4):233-45. doi: 10.1159/000433515. Epub 2015 Aug 25. Review.

3.

Preferences of residents and junior neurologists to attend conferences--an EAYNT survey.

Macerollo A, Róna-Vörös K, Holler N, Chiperi R, Györfi O, Papp V, Sauerbier A, Balicza P, Sellner J.

J Neurol Sci. 2015 Oct 15;357(1-2):297-9. doi: 10.1016/j.jns.2015.06.060. Epub 2015 Jun 28. No abstract available.

PMID:
26145197
4.

E-learning preferences of European junior neurologists-an EAYNT survey.

Sztriha LK, Varga ET, Róna-Vörös K, Holler N, Ilea R, Kobeleva X, Falup-Pecurariu C, Struhal W, Sellner J.

Front Neurol. 2012 Dec 4;3:167. doi: 10.3389/fneur.2012.00167. eCollection 2012. No abstract available.

5.

Resuscitation by hyperbaric exposure from a venous gas emboli following laparoscopic surgery.

Kjeld T, Hansen EG, Holler NG, Rottensten H, Hyldegaard O, Jansen EC.

Scand J Trauma Resusc Emerg Med. 2012 Aug 3;20:51. doi: 10.1186/1757-7241-20-51.

6.

Long-term survival after out-of-hospital cardiac arrest.

Holler NG, Mantoni T, Nielsen SL, Lippert F, Rasmussen LS.

Resuscitation. 2007 Oct;75(1):23-8. Epub 2007 May 3.

PMID:
17481797
7.

Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex.

Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J.

Mol Cell Biol. 2003 Feb;23(4):1428-40.

8.

The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex.

Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW, Briand C, Grütter MG.

J Biol Chem. 2002 Nov 22;277(47):45162-71. Epub 2002 Sep 4.

9.

Ceramide enables fas to cap and kill.

Cremesti A, Paris F, Grassmé H, Holler N, Tschopp J, Fuks Z, Gulbins E, Kolesnick R.

J Biol Chem. 2001 Jun 29;276(26):23954-61. Epub 2001 Apr 3.

10.

IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells.

Werner-Favre C, Bovia F, Schneider P, Holler N, Barnet M, Kindler V, Tschopp J, Zubler RH.

Eur J Immunol. 2001 Jan;31(1):243-9.

11.

Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension.

Kataoka T, Holler N, Micheau O, Martinon F, Tinel A, Hofmann K, Tschopp J.

J Biol Chem. 2001 Jun 1;276(22):19548-54. Epub 2001 Mar 21.

12.

Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.

Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J.

Nat Immunol. 2000 Dec;1(6):489-95.

PMID:
11101870
13.

A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.

Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning JL, Ambrose C, Tschopp J.

J Exp Med. 2000 Dec 4;192(11):1677-84.

16.

The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways.

Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M, Tschopp J.

Curr Biol. 2000 Jun 1;10(11):640-8.

17.

TRAIL receptor-2 signals apoptosis through FADD and caspase-8.

Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J.

Nat Cell Biol. 2000 Apr;2(4):241-3. No abstract available.

PMID:
10783243
18.

Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors.

Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D, Engel J, Tschopp J, Schneider P.

J Immunol Methods. 2000 Apr 3;237(1-2):159-73.

PMID:
10725460
19.
20.

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J.

J Exp Med. 1999 Jun 7;189(11):1747-56.

21.

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE.

Science. 1998 Oct 16;282(5388):490-3.

22.

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.

Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J.

J Exp Med. 1998 Sep 21;188(6):1185-90.

23.
24.

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.

Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J.

Immunity. 1997 Dec;7(6):831-6.

25.

Characterization of two receptors for TRAIL.

Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J.

FEBS Lett. 1997 Oct 27;416(3):329-34.

26.

Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.

Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, Terskikh A, Peitsch MC, Tschopp J.

J Biol Chem. 1997 Jul 25;272(30):18827-33.

Supplemental Content

Loading ...
Support Center